All EGFR Epidermal growth factor receptor antibodies
Epidermal growth factor receptor (EGFR) is a transmembrane protein that is activated by binding of its specific ligands, including epidermal growth factor and transforming growth factor α (TGFα). EGFR is a protein that is found on the surface of some cells that causes cells to divide when epidermal growth factor binds to it. EGFR is a member of the ErbB family of receptors, a subfamily of four closely related receptor tyrosine kinases: EGFR (ErbB-1), HER2/neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). In many cancer types, mutations affecting EGFR expression or activity could result in cancer.
EGFR inhibitors are medicines that bind to certain parts of the EGFR and slow down or stop cell growth. There are several types of EGFR inhibitors including monoclonal antibodies and tyrosine kinase inhibitors. Monoclonal antibodies are laboratory-produced molecules engineered to serve as substitute antibodies that can restore, enhance or mimic the immune system's attack on cancer cells. Tyrosine kinase inhibitors block signals that help cancer cells grow and divide.
EGFR inhibitors have been used in the treatment of several types of cancer including non-small cell lung cancer (NSCLC), colorectal cancer, pancreatic cancer, head and neck cancer, and breast cancer. The use of EGFR inhibitors has been shown to improve overall survival rates in patients with NSCLC. However, not all patients respond to EGFR inhibitors and some may develop resistance over time.
EGFR has been shown to play a role in the development and progression of several types of cancer including NSCLC, colorectal cancer, pancreatic cancer, head and neck cancer, and breast cancer. Inhibition of EGFR has been shown to reduce tumor growth in preclinical models of these cancers.
In summary, Epidermal growth factor receptor (EGFR) is a transmembrane protein that is activated by binding of its specific ligands. EGFR inhibitors are medicines that bind to certain parts of the EGFR and slow down or stop cell growth. EGFR has been shown to play a role in the development and progression of several types of cancer including NSCLC, colorectal cancer, pancreatic cancer, head and neck cancer, and breast cancer. The use of EGFR inhibitors has been shown to improve overall survival rates in patients with NSCLC. However, not all patients respond to EGFR inhibitors and some may develop resistance over time.
Showing 1 - 24 of 2827 results